Hypertension: Synergy of antihypertensives in elderly patients with CKD

Nature Reviews Nephrology

Volumn 9, Issue 1, 2013, Pages 13-15

  Nistala, Ravi ^a   Sowers, James R ^b  

^a University of Missouri   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; AZELNIDIPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; OLMESARTAN; VASODILATOR AGENT;

ARTICLE; BLOOD PRESSURE REGULATION; BRAIN BLOOD VESSEL; CARDIOVASCULAR SYSTEM; CHRONIC KIDNEY DISEASE; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENTIATION; GERIATRIC PATIENT; GLOMERULUS FILTRATION RATE; HEART FAILURE; HUMAN; HYPERTENSION; PATIENT COMPLIANCE; PERIPHERAL EDEMA; PRIORITY JOURNAL;

AGED; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; DRUG SYNERGISM; HUMANS; HYPERTENSION; RENAL INSUFFICIENCY, CHRONIC;

EID: 84871607522     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2012.264     Document Type: Article

References (10)

1. Aronow, W. S. et al. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus documents developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension. J. Am. Coll. Cardiol. 57, 2037-2114 (2011).
2. Kim-Mitsuyama, S. et al. An angiotensin II receptor blocker-calcium channel blocker combination prevents cardiovascular events in elderly high-risk hypertensive patients with chronic kidney disease better than high-dose angiotensin II receptor blockade alone. Kidney Int. http://dx.doi.org/10.1038/ ki.2012.326.
3. Wald, D. S. et al. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am. J. Med. 122, 290-300 (2009).
4. Safar, M. E., Protogerou, A. & Blacher, J. Central blood pressure under angiotensin and calcium channel blockade. Hypertension 54, 704-706 (2009).
5. Kreutz, R. Olmesartan/amlodipine: a review of its use in the management of hypertension. Vasc. Health Risk. Manag. 7, 183-192 (2011).
6. Wang, Y. & Goldhaber, J. I. Return of calcium: Manipulating intracellular calcium to prevent cardiac pathologies. Proc. Natl Acad. Sci. USA 101, 5697-5698 (2004).
7. Hansen, P. B. et al. Functional importance of L-and P/Q-type voltage-gated calcium channels in human renal vasculature. Hypertension 58, 464-470 (2011).
8. + mobilization. Am. J. Physiol. Renal Physiol. 302, F875-F883 (2012).
9. Weir, M. R. et al. Renal outcomes in hypertensive black patients at high cardiovascular risk. Kidney Int. 81, 568-576 (2012).
10. Abe, M. et al. Additive antioxidative effects of azelnidipine on angiotensin receptor blocker olmesartan treatment for type 2 diabetic patients with albuminuria. Hypertens. Res. 34, 935-941 (2011).